Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results

BACKGROUND: Thalidomide is active in multiple myeloma and is associated with minimal myelosuppression, making it a good candidate for induction therapy prior to high-dose therapy with autologous stem-cell transplantation. DESIGN AND METHODS: Oral cyclophosphamide, thalidomide, and dexamethasone was...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Morgan, Gareth J., Davies, Faith E., Gregory, Walter M., Bell, Sue E., Szubert, Alexander J., Navarro Coy, Nuria, Cook, Gordon, Feyler, Sylvia, Johnson, Peter R.E., Rudin, Claudius, Drayson, Mark T., Owen, Roger G., Ross, Fiona M., Russell, Nigel H., Jackson, Graham H., Child, J. Anthony
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Ferrata Storti Foundation 2012
Pynciau:
Original Articles and Brief Reports
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3291601/
https://ncbi.nlm.nih.gov/pubmed/22058209
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2011.043372
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg